Karyopharm Therapeutics. has filed a patent for a crystalline form of a compound represented by Structural Formula 1, along with pharmaceutical compositions containing it. The invention aims to provide treatments for various disorders. The patent also includes methods for preparing the crystalline form of the compound. GlobalData’s report on Karyopharm Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Karyopharm Therapeutics, Targeted cancer therapy was a key innovation area identified from patents. Karyopharm Therapeutics's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline form of compound for pharmaceutical compositions
The patent application US20230391754A1 describes a crystalline form of a compound represented by Structural Formula 1, characterized by specific x-ray powder diffraction peaks and DSC thermograms. The method of preparing this crystalline form involves using a solvent mixture of water and alcohol with specific volume ratios and temperatures, followed by thermal cycling and isolation techniques. The patent also covers a pharmaceutical composition containing the crystalline form for treating CRM1-associated diseases, including various types of cancer, inflammatory disorders, autoimmune disorders, viral infections, and more.
Furthermore, the patent application includes a method for promoting wound healing by administering the crystalline form or the pharmaceutical composition to a subject in need. The therapeutic applications extend to a wide range of disorders, with a particular focus on cancer treatment, including refractory multiple myeloma and penta-refractory multiple myeloma. The detailed description of the crystalline form's characteristics, preparation method, and therapeutic uses provides valuable insights for researchers and pharmaceutical companies looking to develop novel treatments for CRM1-associated diseases and wound healing applications.
To know more about GlobalData’s detailed insights on Karyopharm Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
